GWHP Global Wholehealth Partners Corporation (CE)

Item 1.01 Entry into a Material Definitive Agreement.

On September 15, 2021, Global Wholehealth Partners Corporation (the “Company”) entered into a Memorandum of Understanding (“MOU”) with Avant Gen, Inc. and Pan Probe Biotech to optimize a rapid Covid-19 antigen test currently being developed by AvantGen, Inc. and NanoComposix and/or to develop dipstick-based rapid Covid-19 test by AvantGen, Inc. and the Company. Pan Probe Biotech and the Company working together have developed a very specialized COVID Test using Antibodies which had been approved by National Institute of Health. With Pan Probe Biotech’s technology and the special Antibodies the New generation Test for COVID is available. 

The foregoing description of the MOU does not purport to be completed and is qualified in its entirety by reference to the MOU, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

About AvantGen

AvantGen, Inc is a leader in the use of yeast display technology for antibody discovery and optimization. Founded by experts in the creation of antibody discovery and optimization platforms, AvantGen excels in the rapid generation of antibodies for therapeutic, diagnostic and research tool applications. The Company’s platforms include a robust yeast display system, large natural human antibody database, fully human antibody libraries comprised of over 100 billion antibody clones displayed by yeast cells, NK and T cell engager technology, flow cytometry-based and other screening technologies, as well as novel methodologies for rabbit monoclonal antibody generation. These versatile platforms can be used to discover and optimize antibodies directed at specific disease targets, affinity mature existing antibodies to improve their binding properties and humanize antibodies to render non-human antibodies suitable for human therapeutic applications, as well as generate rabbit monoclonal antibodies for applications that need extremely high specificity, such as antibodies capable of distinguishing point mutations and post-translational modifications for IHC, and anti-idiotype antibodies for PK studies. AvantGen’s partners include pharmaceutical, biotech, diagnostic and government entities, many of which are repeat customers.

About Pan Probe Biotech

Pan Probe Biotech is a manufacturer and supplier of quality, rapid diagnostic test kits/medical devices. We offer a variety of products suitable for point-of-care use in the clinical setting, for forensic diagnostics and for research purposes. Our product lines focus specifically on rapid tests to detect drugs of abuse, fertility, ovulation & pregnancy, with significant, additional efforts in infectious disease & cancer detection. Our tumor marker rapid test products include diagnostic kits for the detection of fecal occult bleeding (FOB) and prostate specific antigen (PSA). The PSA tests include a semi-quantitative test that provides a third band as an in-test quantitative reference. The products exist for both blood serum and whole blood. The FOB test uses prepared fecal samples but can also detect blood in urine. The tumor marker diagnostic kits come with accessories and running buffers. Tests are designed to be read within ten minutes.